The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could ...
Merck (NYSE:MRK) reported positive Phase 2b results for tulisokibart in moderate to severe hidradenitis suppurativa on 1 ...
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused approach to the research and development of ...
Merck's (NYSE:MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, demonstrated encouraging antitumor activity in the phase 2 portion of a study of ...
Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...
Merck (MRK) on Wednesday announced that it succeeded in a mid-stage trial for tulisokibart, its experimental therapy for an inflammatory skin condition known as hidradenitis suppurativa, positioning ...
Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...
Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...
The Food and Drug Administration has cleared a new preventative option designed to protect infants from respiratory syncytial virus. Called Enflonsia and developed by Merck & Co., the drug is an ...
Drugmaker Merck is testing its antibody-drug conjugates (ADCs) alone and with its signature immunotherapy drug Keytruda across breast cancer and several gynecologic cancers, including endometrial, ...
March 31 (Reuters) - Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck, that could be worth up to about $838 million in milestone payments, to discover and develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results